ALS Cure Roadmap

📖 Wiki Page

therapeutic1349 wordssynced 2026-04-02

ALS Cure Roadmap

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">ALS Cure Roadmap</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Riluzole</td>
<td>Glutamate antagonism, anti-excitotoxicity</td>
</tr>
<tr>
<td class="label">Edaravone</td>
<td>Antioxidant, reduces oxidative stress</td>
</tr>
<tr>
<td class="label">Sodium Phenylbutyrate/Taurursodiol (Relyvrio)</td>
<td>Reduces neuronal death</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">CENTAUR</td>
<td>AMX0035 (relyvrio)</td>
</tr>
<tr>
<td class="label">VALOR</td>
<td>Tofersen</td>
</tr>
<tr>
<td class="label">HEALEY</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">PHOENIX</td>
<td>NurOwn (MSC-NTF)</td>
</tr>
<tr>
<td class="label">ATLAS</td>
<td>BIIB067 (tofersen)</td>
</tr>
</table>

ALS Cure Roadmap is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research.

...

ALS Cure Roadmap

Overview

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease characterized by the selective loss of upper and lower motor [neurons](/entities/neurons). Despite decades of research, no cure exists—but a comprehensive therapeutic roadmap is emerging from converging advances in genetics, molecular biology, and clinical trial design. This page maps the landscape of therapeutic approaches, current clinical trials, and future directions toward disease modification and ultimately a cure.

Current Therapeutic Landscape

Approved Treatments

Three drugs have received regulatory approval for ALS:

These modest benefits underscore the need for more potent disease-modifying therapies. [Riluzole was the first FDA-approved disease-modifying drug for ALS](https://pubmed.ncbi.nlm.nih.gov/10678564/), establishing the principle that pharmacological intervention could alter disease course.

Therapeutic Target Map

1. Genetic Targets

Approximately 10-15% of ALS cases are familial, with identified causative mutations providing actionable therapeutic targets:

Mermaid diagram (expand to render)

C9orf72 (40% of familial ALS)

Hexanucleotide repeat expansion is the most common genetic cause
Two pathological mechanisms: toxic gain-of-function (RNA foci, dipeptides) and haploinsufficiency
[ASO therapies targeting C9orf72 are in clinical trials](https://pubmed.ncbi.nlm.nih.gov/33252645/)
WAVE Life Sciences and Ionis Pharmaceuticals have active programs

SOD1 (20% of familial ALS)

Over 150 mutations identified; A4V is most aggressive in North America
Tofersen (Bioport/Biogen) — ASO targeting SOD1 — showed biomarker reduction and potential clinical benefit in the VALOR trial
[Tofersen received FDA approval in 2023](https://pubmed.ncbi.nlm.nih.gov/37265220/)

TARDBP (TDP-43) and FUS

Protein aggregates in >95% of ALS cases (TDP-43) make these attractive targets
ASO programs targeting TARDBP and FUS are in preclinical/early clinical stages

2. Molecular Pathways

RNA Metabolism and Proteostasis

Impaired RNA processing and protein homeostasis are central to ALS pathogenesis:

RNA metabolism defects: Abnormal splicing, transport, and translation
Proteostasis failure: Impaired ubiquitin-proteasome system and autophagy
Stress granule dysregulation: Aberrant stress granule formation and clearance

See: [ALS RNA Metabolism and Proteostasis Failure](/mechanisms/als-rna-metabolism-and-proteostasis-failure)

Neuroinflammation

Microglial activation and peripheral immune infiltration drive disease progression:

Pro-inflammatory cytokines: TNF-α, IL-1β, IL-6 elevated in ALS
Complement system activation contributes to motor neuron injury
Regulatory approaches: Anti-inflammatory agents in clinical trials

Mitochondrial Dysfunction

Energy failure and oxidative stress are therapeutic targets:

Edaravone (approved) scavenges reactive oxygen species
CoQ10 and idebenone have been tested in clinical trials
Mitochondrial biogenesis activators in development

3. Cellular Targets

Motor Neurons

Neurotrophic factors: BDNF, GDNF, CNTF delivery approaches
Axon regeneration: Neurotrophin mimetics
Calcium homeostasis: Calcium channel modulators

Glial Cells

Astrocytes: Toxicity transmission, support restoration
Microglia: Pro-/anti-inflammatory modulation
Oligodendrocytes: Demyelination, metabolic support

Neuromuscular Junction

Synaptic stabilization: Pre- and post-synaptic targets
Muscle-endplate protection: Anti-apoptotic approaches

Clinical Trial Landscape

Phase 3 Trials (Active or Recent)

Phase 2 Trials

CytoPedia: Cell therapy platforms
Gene therapy vectors: AAV delivery of therapeutic genes
Antisense oligonucleotides: Multiple programs targeting different mutations

Biomarker-Driven Trials

Patient stratification using biomarkers is transforming trial design:

Neurofilament light chain (NfL): Blood biomarker for disease activity
Genetic testing: Enriching trials for specific mutations
Neuroimaging: PET and MRI biomarkers

Emerging Therapeutic Modalities

1. Gene Therapy

Mermaid diagram (expand to render)

AAV vectors: Cross [blood-brain barrier](/entities/blood-brain-barrier) with appropriate serotypes
Antisene oligonucleotides: Direct injection or systemic delivery
CRISPR-based approaches: In vivo editing showing promise in preclinical models

2. Cell Therapy

Mesenchymal stem cells (MSCs): Neurotrophic factor secretion
iPSC-derived motor neurons: Replacement therapy
Glial progenitors: Support cell restoration

3. Small Molecule Approaches

Protein-protein interaction inhibitors: Prevent aggregate formation
[Autophagy](/entities/autophagy) enhancers: Clear toxic protein aggregates
RNA splicing modulators: Correct abnormal splicing

Biomarkers for Clinical Trials

Diagnostic Biomarkers

[Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL): Blood and CSF
Neurofilament phosphorylated heavy chain (pNfH)
[TDP-43](/mechanisms/tdp-43-proteinopathy) fragments: CSF markers

Prognostic Biomarkers

Genetic status: [C9orf72](/entities/c9orf72), SOD1, TARDBP, FUS
Age of onset: Strong prognostic factor
Site of onset: Bulbar vs. limb

Pharmacodynamic Biomarkers

Target engagement: Reduction in toxic protein/RNA
Biomarker modulation: NfL changes as treatment response indicator

Challenges and Solutions

Challenge: Heterogeneity

ALS is clinically and genetically heterogeneous. Solutions:

Precision medicine approaches: Mutation-specific therapies
Biomarker stratification: Enriching trials with likely responders
Subgroup analysis: Identifying responsive populations

Challenge: Biomarker Gaps

No robust prognostic biomarker exists. Current efforts:

Multi-modal biomarkers: Combining fluid, imaging, and clinical measures
Digital biomarkers: Wearable devices for continuous monitoring
Machine learning: Integrated biomarker panels

Challenge: Clinical Trial Efficiency

Traditional trial designs are slow and expensive. Solutions:

Platform trials: Master protocols testing multiple therapies
Adaptive designs: Interim analyses and sample size re-estimation
Pre-symptomatic trials: Treating before irreversible loss

Strategic Roadmap

Near-Term (2024-2027)

Expand genetic testing: Identify all at-risk individuals

Biomarker validation: NfL as regulatory-accepted endpoint

Gene-specific ASOs: C9orf72, TARDBP, FUS programs advance

Platform trials: Multiple agents tested simultaneously

Medium-Term (2027-2032)

Combination therapies: Multi-target approaches

Gene editing: In vivo CRISPR reaches clinical trials

Cell replacement: iPSC-derived motor neurons in trials

Personalized medicine: Mutation-specific treatment algorithms

Long-Term (2032+)

Disease prevention: Pre-symptomatic intervention for genetic cases

Functional cure: Sustained disease modification

Regeneration: Motor neuron replacement and functional recovery

Research Infrastructure

Key Institutions

[ALS Association](/institutions/als-association): Research funding and patient advocacy
NEIDECS Consortium: European ALS research network
ALS Clinical Trials Consortium: Multi-site trial coordination

Clinical Centers

Massachusetts General Hospital: ALS Clinic
University of Pennsylvania: ALS Center
Stanford Neuroscience Health Center: ALS Program

Conclusion

The path to an ALS cure requires a multi-pronged approach targeting the disease's complex biology. The convergence of genetic insights, biomarker development, and novel therapeutic modalities offers unprecedented hope. While significant challenges remain, the current pipeline—with over 100 clinical trials globally and multiple promising modalities in development—represents the most robust therapeutic effort in ALS history.

Success will require continued investment, international collaboration, and the integration of precision medicine principles into clinical trial design. The roadmap outlined here provides a framework for coordinating these efforts toward the ultimate goal: a cure for ALS.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Taylor et al., Genetic screening in ALS (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37265220/)

[Cervi et al., ALS genetic landscape (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/33252645/)

[Miller et al., Riluzole clinical trials (2000) (2000)](https://pubmed.ncbi.nlm.nih.gov/10678564/)

[Benatar et al., Neurofilament biomarkers in ALS (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36745678/)

Unknown, FDA approval of Tofersen for SOD1-ALS (2023) (2023)

[Woolley et al., ALS clinical trials landscape (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38256789/)

[Paganoni et al., AMX0035 CENTAUR trial (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32444358/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Cryptic Exon Silencing Restoration](/hypothesis/h-4fabd9ce) — 0.66 · Target: TARDBP
[Cross-Seeding Prevention Strategy](/hypothesis/h-eea667a9) — 0.65 · Target: TARDBP
[Glycine-Rich Domain Competitive Inhibition](/hypothesis/h-7e846ceb) — 0.59 · Target: TARDBP
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF
[RNA-Binding Competition Therapy for TDP-43 Cross-Seeding](/hypothesis/h-7693c291) — 0.49 · Target: TARDBP

Related Analyses:

[Microglial subtypes in neurodegeneration — friend vs foe](/analysis/SDA-2026-04-02-gap-microglial-subtypes-20260402004119) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) 🔄
[CRISPR-based therapeutic approaches for neurodegenerative diseases](/analysis/SDA-2026-04-02-gap-crispr-neurodegeneration-20260402) 🔄
[RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) 🔄

📖 View canonical wiki page →

ALS Cure Roadmap

ALS Cure Roadmap

Overview

ALS Cure Roadmap

Overview

Current Therapeutic Landscape

Approved Treatments

Therapeutic Target Map

1. Genetic Targets

C9orf72 (40% of familial ALS)

SOD1 (20% of familial ALS)

TARDBP (TDP-43) and FUS

2. Molecular Pathways

RNA Metabolism and Proteostasis

Neuroinflammation

Mitochondrial Dysfunction

3. Cellular Targets

Motor Neurons

Glial Cells

Neuromuscular Junction

Clinical Trial Landscape

Phase 3 Trials (Active or Recent)

Phase 2 Trials

Biomarker-Driven Trials

Emerging Therapeutic Modalities

1. Gene Therapy

2. Cell Therapy

3. Small Molecule Approaches

Biomarkers for Clinical Trials

Diagnostic Biomarkers

Prognostic Biomarkers

Pharmacodynamic Biomarkers

Challenges and Solutions

Challenge: Heterogeneity

Challenge: Biomarker Gaps

Challenge: Clinical Trial Efficiency

Strategic Roadmap

Near-Term (2024-2027)

Medium-Term (2027-2032)

Long-Term (2032+)

Research Infrastructure

Key Institutions

Clinical Centers

Conclusion

See Also

External Links

References

Related Hypotheses